WESFARMERS LIMITED (WES)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

WES - WESFARMERS LIMITED

FNArena Sector : Apparel & Footwear
Year End: June
GICS Industry Group : Food & Staples Retailing
Index: ASX20 | ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Wesfarmer is an Australian conglomerate with interests predominantly in Australian and New Zealand retail companies. It owns Bunnings, Kmart, Officeworks and Target, amongst others. Founded as the Westralian Farmers Co-operative in 1914 it became a listed entity in November 1984.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$61.14

30 Jul
2021

-0.290

OPEN

$61.64

-0.47%

HIGH

$61.83

1,549,795

LOW

$60.81

TARGET
$53.733 -12.1% downside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
MYR . PBG . PMV . CCX . SRF . PGR . MOZ . AX1 . BBN . UNI . CTT .
FNARENA'S MARKET CONSENSUS FORECASTS
WES: 1
Title FY19
Actual
FY20
Actual
FY21
Forecast
FY22
Forecast
EPS (cps) xxx 150.0 207.8 xxx
DPS (cps) xxx 170.0 171.5 xxx
EPS Growth xxx - 28.0% 38.5% xxx
DPS Growth xxx - 88.9% 0.9% xxx
PE Ratio xxx N/A 29.4 xxx
Dividend Yield xxx N/A 2.8% xxx
Div Pay Ratio(%) xxx 113.3% 82.5% xxx

Dividend yield today if purchased 3 years ago: 3.42%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

2.78

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 23/02 - 88c (100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2021 FactSet UK Limited. All rights reserved
Title 201520162017201820192020
EPS Basic xxxxxxxxxxxxxxx150.0
DPS All xxxxxxxxxxxxxxx170.0
Sales/Revenue xxxxxxxxxxxxxxx30,753.0 M
Book Value Per Share xxxxxxxxxxxxxxx824.1
Net Operating Cash Flow xxxxxxxxxxxxxxx4,546.0 M
Net Profit Margin xxxxxxxxxxxxxxx5.27 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

7
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

5

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Credit Suisse

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

13/07/2021

3

Equal-weight

$52.00

-14.95%

Morgan Stanley considers, at face value, the proposed acquisition of Australian Pharmaceutical Industries is relatively small although, as Wesfarmers stated this could form the basis of a new health care division, and presumably be a platform for growth.

The transaction is expected to be funded by the existing balance sheet and debt facilities and is subject to due diligence and ACCC clearance.

Morgan Stanley retains an Equal-weight rating and the target price of $52. Industry view is Attractive.

FORECAST
Morgan Stanley forecasts a full year FY21 dividend of 158.00 cents and EPS of 210.00 cents.
Morgan Stanley forecasts a full year FY22 dividend of 157.00 cents and EPS of 196.00 cents.

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

WES STOCK CHART